Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prime Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prime Medicine's regulatory disclosures and financial reporting.
Prime Medicine, Inc. reported full-year 2025 results and detailed progress across its gene-editing pipeline. Total collaboration revenue was $4.6M, up from $3.0M in 2024, while research and development expenses rose to $160.6M and general and administrative expenses to $52.3M. Net loss widened slightly to $201.1M, or $1.35 per share, compared with a $195.9M loss, or $1.65 per share, a year earlier. Cash, cash equivalents, investments and restricted cash totaled $191.4M as of December 31, 2025, and the company expects this to fund operations into 2027.
Prime highlighted “breakthrough” Phase 1/2 data for PM359 in chronic granulomatous disease and is working toward final FDA alignment to submit a biologics license application. It plans to file IND and/or CTA applications for its Wilson Disease program PM577 in the first half of 2026 and for its Alpha-1 Antitrypsin Deficiency program PM647 in mid-2026, with initial clinical data for both targeted in 2027. The company is also advancing a cystic fibrosis program supported by the Cystic Fibrosis Foundation and continues its ex vivo CAR-T collaboration with Bristol Myers Squibb, positioning its Prime Editing platform for broader clinical validation.
Reine Allan reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Executive Officer Reine Allan received a grant of stock options for 1,300,000 shares of company stock. The options were awarded on February 26, 2026 and are held directly. They vest in substantially equal monthly installments, with 1/48 of the underlying shares vesting on each monthly anniversary of February 26, 2026, as long as Allan continues in service on each vesting date.
LEE ANN L. reported acquisition or exercise transactions in this Form 4 filing.
Prime Medicine, Inc. reported that Chief Technical Officer Lee Ann L. received a grant of stock options covering 375,000 shares of common stock. According to the terms, 1/48th of the option vests in substantially equal monthly installments starting on February 23, 2026, subject to her continued service, aligning this award with long-term employment and company performance.
Prime Medicine, Inc. reported that officer Alenson Carman acquired a stock option covering 140,000 shares of the company’s stock. This was recorded as a grant or award transaction.
According to the vesting terms, 1/48th of the option vests in substantially equal monthly installments on each monthly anniversary of February 23, 2026, conditioned on Carman’s continued service on each vesting date.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 5,995,183 shares of Prime Medicine Inc. common stock, representing 3.3% of the class as of 12/31/2025. The firm has sole voting and dispositive power over all of these shares.
The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Prime Medicine. The filer also states that this report should not be construed as an admission that it is the beneficial owner of these securities.
Prime Medicine, Inc. furnished an updated corporate presentation on its investor website, with the materials attached as Exhibit 99.1. The presentation, dated January 2026, is provided under a Regulation FD disclosure to share information with the market in a broadly accessible way. The company states that this information is being furnished rather than filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
Prime Medicine (PRME) filed its Q3 2025 10‑Q, highlighting a development‑stage profile with modest collaboration revenue and ongoing investment in programs. Total revenue was $1.2 million in the quarter, while the net loss was $50.6 million or $(0.32) per share. Year to date, revenue reached $3.8 million with a net loss of $155.1 million.
Operating expenses reflected pipeline progress and footprint expansion: R&D was $44.0 million and G&A was $11.2 million in Q3. Cash used in operations for the first nine months was $125.3 million. The balance sheet shows $71.4 million in cash and cash equivalents and $137.0 million in short‑term investments, totaling $213.3 million in cash, cash equivalents, and investments as of September 30, 2025. Management states this is sufficient to fund operations for at least twelve months from issuance.
In August 2025, the company completed a public offering of 43.7 million shares at $3.30 per share for $138.4 million in net proceeds. As of September 30, 2025, 180,309,471 shares were outstanding. Prime Medicine also recorded an $18.0 million research funding liability tied to external funding arrangements.
Prime Medicine, Inc. (PRME) furnished an 8‑K to announce it issued a press release covering financial results and business highlights for the quarter ended September 30, 2025.
The disclosure was made under Item 2.02 and includes Exhibit 99.1 (Press Release dated November 7, 2025). The information is furnished and shall not be deemed filed under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly stated by specific reference.
Prime Medicine’s common stock trades on The Nasdaq Global Market under the symbol PRME.
Prime Medicine, Inc. furnished a corporate update through a new investor presentation posted on its website on September 8, 2025. The company made the presentation, dated September 2025, available as Exhibit 99.1 to this report under a Regulation FD disclosure item.
The material is being treated as furnished, not filed, which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
ARCH Venture group and certain affiliated funds and individuals report collective beneficial ownership of 18,486,894 shares of Prime Medicine common stock, representing 10.4% of the outstanding class on the basis described in this filing. The disclosure aggregates holdings across multiple ARCH entities and related partnerships and shows shared voting and dispositive power over those shares.
The filing also discloses that AVF XII purchased 3,030,300 shares at $3.30 per share in a public offering, for total consideration of $9,999,990, funded from AVF XII working capital. The amendment was filed because an issuer offering (an August 2025 issuance of 43,700,000 shares) changed the Reporting Persons' percentage ownership by one percent or more. The statement notes existing registration rights under an Amended and Restated Investors' Rights Agreement and that no Reporting Person was subject to disqualifying legal proceedings in the prior five years.